Mindray Medical International Ltd Given Average Recommendation of “Hold” by Analysts (NYSE:MR)
Mindray Medical International Ltd (NYSE:MR) has earned a consensus recommendation of “Hold” from the eight ratings firms that are covering the stock, StockRatingsNetwork reports. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $36.30.
Shares of Mindray Medical International Ltd (NYSE:MR) traded up 0.23% during mid-day trading on Wednesday, hitting $30.65. The stock had a trading volume of 48,529 shares. Mindray Medical International Ltd has a 52-week low of $29.94 and a 52-week high of $43.81. The stock has a 50-day moving average of $32.05 and a 200-day moving average of $35.14. The company has a market cap of $3.582 billion and a P/E ratio of 18.07.
Mindray Medical International Ltd (NYSE:MR) last announced its earnings results on Monday, May 5th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.02. The company had revenue of $264.80 million for the quarter, compared to the consensus estimate of $292.50 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, analysts predict that Mindray Medical International Ltd will post $1.88 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Mindray Medical International Ltd from $36.00 to $32.00 in a research note on Thursday, May 22nd. They now have a “hold” rating on the stock. Separately, analysts at Bank of America downgraded shares of Mindray Medical International Ltd from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 7th. Finally, analysts at Morgan Stanley reiterated an “in-line” rating on shares of Mindray Medical International Ltd in a research note on Tuesday, May 6th.
Mindray Medical International Limited (NYSE:MR), is a developer, manufacturer and marketer of medical devices worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.